Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways

Radiotherapy and Oncology

Volumn 105, Issue 2, 2012, Pages 241-249

  Raju, Uma ^a   Riesterer, Oliver ^a   Wang, Zhi Qiang ^a   Molkentine, David P ^a   Molkentine, Jessica M ^a   Johnson, Faye M ^a,b   Glisson, Bonnie ^a   Milas, Luka ^a   Ang, K Kian ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

c Src; DNA repair; EGFR; Head and neck cancer; Radiation sensitivity

Indexed keywords

DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HISTONE H2AX; PROTEIN KINASE P60;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CONTROL; CANCER RADIOTHERAPY; CELL SURVIVAL; DNA REPAIR; DRUG MECHANISM; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIATION DOSE; RADIOSENSITIVITY; WESTERN BLOTTING;

ACTIVE TRANSPORT, CELL NUCLEUS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL NUCLEUS; DNA REPAIR; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HEAD AND NECK NEOPLASMS; HUMANS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RADIATION TOLERANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SRC-FAMILY KINASES; THIAZOLES;

EID: 84871300677     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2012.08.010     Document Type: Article

References (51)

1. J.A. Bonner, P.M. Harari, and J. Giralt Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 2006 567 578
2. R.B. Irby, and T.J. Yeatman Role of Src expression and activation in human cancer Oncogene 19 2000 5636 5642
3. G.S. Martin The road to Src Oncogene 23 2004 7910 7917
4. T.J. Yeatman A renaissance for SRC Nat Rev Cancer 4 2004 470 480
5. S.K. Mitra, and D.D. Schlaepfer Integrin-regulated FAK-Src signaling in normal and cancer cells Curr Opin Cell Biol 18 2006 516 523
6. T. Chen, J.A. George, and C.C. Taylor Src tyrosine kinase as a chemotherapeutic target: is there a clinical case? Anticancer Drugs 17 2006 123 131
7. M.G. van Oijen, G. Rijksen, F.W. ten Broek, and P.J. Slootweg Overexpression of c-Src in areas of hyperproliferation in head and neck cancer, premalignant lesions and benign mucosal disorders J Oral Pathol Med 27 1998 147 152
8. M. Mandal, J.N. Myers, and S.M. Lippman Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features Cancer 112 2008 2088 2100
9. R. Bu, K.R. Purushotham, and M. Kerr Alterations in the level of phosphotyrosine signal transduction constituents in human parotid tumors Proc Soc Exp Biol Med 211 1996 257 264
10. A. Myoui, R. Nishimura, and P.J. Williams C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis Cancer Res 63 2003 5028 5033
11. Q. Zhang, S.M. Thomas, and S. Xi SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells Cancer Res 64 2004 6166 6173
12. K.A. DeMali, S.L. Godwin, S.P. Soltoff, and A. Kazlauskas Multiple roles for Src in a PDGF-stimulated cell Exp Cell Res 253 1999 271 279
13. E. Landgren, P. Blume-Jensen, S.A. Courtneidge, and L. Claesson-Welsh Fibroblast growth factor receptor-1 regulation of Src family kinases Oncogene 10 1995 2027 2035
14. S. Huveneers, I. van den Bout, P. Sonneveld, A. Sancho, A. Sonnenberg, and E.H. Danen Integrin alpha v beta 3 controls activity and oncogenic potential of primed c-Src Cancer Res 67 2007 2693 2700
15. D.A. Tice, J.S. Biscardi, A.L. Nickles, and S.J. Parsons Mechanism of biological synergy between cellular Src and epidermal growth factor receptor Proc Natl Acad Sci USA 96 1999 1415 1420
16. T.H. Leu, and M.C. Maa Functional implication of the interaction between EGF receptor and c-Src Front Biosci 8 2003 s28 s38
17. J. Zhang, S. Kalyankrishna, and M. Wislez SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines Am J Pathol 170 2007 366 376
18. J.X. Zou, Y. Liu, E.B. Pasquale, and E. Ruoslahti Activated SRC oncogene phosphorylates R-ras and suppresses integrin activity J Biol Chem 277 2002 1824 1827
19. A.D. Laird, G. Li, and K.G. Moss Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells Mol Cancer Ther 2 2003 461 469
20. R. Karni, R. Jove, and A. Levitzki Inhibition of pp 60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors Oncogene 18 1999 4654 4662
21. J.F. Bromberg Activation of STAT proteins and growth control Bioessays 23 2001 161 169
22. R. Zheng, S. Yano, and Y. Matsumori SRC tyrosine kinase inhibitor, m475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells Clin Exp Metastasis 22 2005 195 204
23. I. Ischenko, M. Guba, and M. Yezhelyev Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer Angiogenesis 10 2007 167 182
24. H. Jallal, M.L. Valentino, G. Chen, F. Boschelli, S. Ali, and S.A. Rabbani A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo Cancer Res 67 2007 1580 1588
25. Z. Li, Y. Hosoi, and K. Cai Src tyrosine kinase inhibitor PP2 suppresses ERK1/2 activation and epidermal growth factor receptor transactivation by X-irradiation Biochem Biophys Res Commun 341 2006 363 368
26. L.J. Lombardo, F.Y. Lee, and P. Chen Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays J Med Chem 47 2004 6658 6661
27. A. Quintas-Cardama, H. Kantarjian, and J. Cortes Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib Future Oncol 2 2006 655 665
28. R.S. Finn, J. Dering, and C. Ginther Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro Breast Cancer Res Treat 105 2007 319 326
29. A. Serrels, I.R. Macpherson, and T.R. Evans Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib Mol Cancer Ther 5 2006 3014 3022
30. F.M. Johnson, B. Saigal, M. Talpaz, and N.J. Donato Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells Clin Cancer Res 11 2005 6924 6932
31. S. Kopetz, D.P. Lesslie, and N.A. Dallas Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress Cancer Res 69 2009 3842 3849
32. A.S. Tsao, D. He, and B. Saigal Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion Mol Cancer Ther 6 2007 1962 1972
33. F.M. Johnson, B.N. Bekele, and L. Feng Phase II study of dasatinib in patients with advanced non-small-cell lung cancer J Clin Oncol 28 2010 4609 4615
34. H.D. Brooks, B.S. Glisson, and B.N. Bekele Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma Cancer 117 2011 2112 2119
35. J.M. Summy, and G.E. Gallick Treatment for advanced tumors: SRC reclaims center stage Clin Cancer Res 12 2006 1398 1401
36. C.S. Pichot, S.M. Hartig, and L. Xia Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells Br J Cancer 101 2009 38 47
37. E.B. Haura, T. Tanvetyanon, and A. Chiappori Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer J Clin Oncol 28 2010 1387 1394
38. K.C. Cuneo, L. Geng, and J. Tan SRC family kinase inhibitor SU6656 enhances antiangiogenic effect of irradiation Int J Radiat Oncol Biol Phys 64 2006 1197 1203
39. P.R. Purnell, P.C. Mack, and C.G. Tepper The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells J Thorac Oncol 4 2009 448 454
40. U. Raju, E. Nakata, K.A. Mason, K.K. Ang, and L. Milas Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells Cancer Res 63 2003 3263 3267
41. B. Fertil, and E.P. Malaise Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy Int J Radiat Oncol Biol Phys 7 1981 621 629
42. L. Song, M. Morris, T. Bagui, F.Y. Lee, R. Jove, and E.B. Haura Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival Cancer Res 66 2006 5542 5548
43. S. Nam, D. Kim, and J.Q. Cheng Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells Cancer Res 65 2005 9185 9189
44. B. Sen, S. Peng, B. Saigal, M.D. Williams, and F.M. Johnson Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer Clin Cancer Res 17 2011 514 524
45. B. Sen, B. Saigal, N. Parikh, G. Gallick, and F.M. Johnson Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding Cancer Res 69 2009 1958 1965
46. V. Singh-Gupta, H. Zhang, and S. Banerjee Radiation-induced HIF-1alpha cell survival pathway is inhibited by soy isoflavones in prostate cancer cells Int J Cancer 124 2009 1675 1684
47. J. Bartkova, J. Tommiska, and L. Oplustilova Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene Mol Oncol 2 2008 296 316
48. T. Uziel, Y. Lerenthal, L. Moyal, Y. Andegeko, L. Mittelman, and Y. Shiloh Requirement of the MRN complex for ATM activation by DNA damage EMBO J 22 2003 5612 5621
49. K. Dittmann, C. Mayer, and B. Fehrenbacher Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase J Biol Chem 280 2005 31182 31189
50. C. Li, M. Iida, E.F. Dunn, and D.L. Wheeler Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma Radiother Oncol 97 2010 330 337
51. R.E. Meyn, L. Milas, and K.K. Ang The role of apoptosis in radiation oncology Int J Radiat Biol 85 2009 107 115